A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865; IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive; Recurrent Ovarian; Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865; IND #113912)(12/19/2011) (10/01/12) NCT# 00565851